Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape

Bacterial cancer therapy (BCT) shows great promise for treatment of solid tumors, yet basic mechanisms of bacterial-induced tumor suppression remain undefined. Attenuated strains of Salmonella enterica serovar Typhimurium (STm) have commonly been used in mouse models of BCT in xenograft and orthotopic transplant cancer models. We aimed to better understand the tumor epithelium-targeted mechanisms of BCT by using autochthonous mouse models of intestinal cancer and tumor organoid cultures to assess the effectiveness and consequences of oral treatment with aromatase A-deficient STm (STm Delta aroA). STm Delta aroA delivered by oral gavage significantly reduced tumor burden and tumor load in both a colitis-associated colorectal cancer (CAC) model and in a spontaneous Apr(min/+) intestinal cancer model. STm Delta aroA colonization of tumors caused alterations in transcription of mRNAs associated with tumor sternness, epithelialmesenchymal transition, and cell cycle. Metabolomic analysis of tumors demonstrated alteration in the metabolic environment of STm Delta aroA-treated tumors, suggesting that imposes metabolic competition on the tumor. Use of tumor organoid cultures in vitro recapitulated effects seen on tumor sternness, mesenchymal markers, and altered metabolome. Furthermore, live STm Delta aroA was required, demonstrating active mechanisms including metabolite usage. We have demonstrated that oral BET is efficacious in autochthonous intestinal cancer models, that BET imposes metabolic competition, and that BET has direct effects on the tumor epithelium affecting tumor stem cells.

Automated summary

The study demonstrates that oral treatment with aromatase A-deficient STm is effective in autochthonous intestinal cancer models, imposes metabolic competition on tumors, and directly affects tumor epithelium, impacting tumor stem cells.